Multimodality treatment for hormone-naïve metastatic prostate cancer
Docetaxel for prostate cancer: Best timing and right patient
Date
09 Oct 2016Session
Multimodality treatment for hormone-naïve metastatic prostate cancerPresenters
Nick JamesAuthors
N. JamesAuthor affiliations
- Cancer And Genomic Sciences, University of Birmingham, B15 2TT - Birmingham/GB
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Radiation to the primary tumour in metastatic disease: When and whom
Presenter: Alberto Bossi
Session: Multimodality treatment for hormone-naïve metastatic prostate cancer
Resources:
Webcast
Does radical prostatectomy have an impact on long-term outcomes of patients with metastatic prostate cancer?
Presenter: Axel Heidenreich
Session: Multimodality treatment for hormone-naïve metastatic prostate cancer
Resources:
Slides
Webcast